CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq: DYAX) announced today that it has granted a non-exclusive license to its proprietary antibody phage display libraries to ZymoGenetics, Inc. (Nasdaq: ZGEN) for the discovery of therapeutic antibodies. This collaboration with ZymoGenetics is part of Dyax’s Licensing and Funded Research Program (LFRP) partnered with Paul Royalty Fund. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from ZymoGenetics’s use of the Dyax libraries. The agreement provides ZymoGenetics a license to Dyax’s antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’s antibody phage display technology.
